细胞因子信号转导负调控因子家族

JAK／STAT是细胞因子发挥生物学功能的重要信号转导途径。作为抑制JAK／STAT途径的蛋白质－细胞因子信号转导负调控因子SOCS家族,目前已知有8个成员,细胞因子通过JAK／STAT通路调节该家族蛋白表达。近年来基因敲除在SOCS研究领域的广泛应用初步阐明了SOCS在体内的生物学功能。     

SOCS1与肿瘤发生、发展和治疗的研究进展

SOCS1是细胞因子信号转导抑制因子(SOCS)蛋白家族的重要成员,近年来随着对SOCS1研究的深入,它的各种功能逐渐被发现。SOCS1的作用机制复杂,可以被体内多种细胞因子诱导,然后抑制下游的细胞因子和生长因子受体信号活化。SOCS1参与了体内多种急慢性炎症反应、先天性及获得性免疫反应、激素的调节以及多种肿瘤的生成和发展等,尤其是它与肿瘤的关系成为近期研究的热点。SOCS1基因目前被认为是一种新的抑癌基因,研究表明SOCS1基因甲基化、突变以及缺失导致的SOCS1表达减少在肿瘤的形成、发展过程中起重要作用。近年来对于恢复SOCS1的表达可以用来治疗肿瘤方面的研究逐渐增多,有些方法已经应用于临床,而且取得了一定的成果。本文就近年来SOCS1在肿瘤领域中的研究进展进行了综述。     

SOCS3在病理性疼痛中的作用

细胞因子信号传导抑制因子3(SOCS3)是细胞因子信号传导抑制因子蛋白质家族(SOCS)的一员。SOCS3是一种重要的细胞内蛋白质,在体内负调控细胞因子介导的信号通路,参与机体免疫、生长、造血、新陈代谢及肿瘤增殖等各种关键过程。近年的研究发现,SOCS3参与疼痛的调控,在神经病理性疼痛、炎性疼痛等多种类型疼痛及吗啡耐受中发生表达的变化。在坐骨神经慢性压迫损伤(CCI)模型中,磷酸二聚化的STAT3转移到细胞核内诱导脊髓背角SOCS3表达增加,在完全弗氏佐剂(CFA)炎性疼痛大鼠中,下丘脑室旁核(PVN)内SOCS3在急性期蛋白质表达水平增加、其慢性期表达下降,在骨癌疼痛大鼠腰2～5背根神经节(DRG)中SOCS3蛋白质水平显著下降。鞘内注射SOCS3慢病毒载体、阿司匹林触发的脂蛋白A4(ATL)和芍药苷,或通过抑制非编码RNA表达降低非编码RNA对SOCS3的抑制作用,能够增加SOCS3表达发挥镇痛作用。SOCS3通过抑制Janus激酶/信号转导子和转录激活子3(JAK/STAT3)信号通路及下游基因的表达,阻碍白细胞介素-1(IL-1)、IL-6和肿瘤坏死因子α(TNF-α)等多种炎...     

细胞因子信号转导的负性调节因子SOCS—1的研究进展

SOCS是新近发现的一类与细胞因子JAK-STAT信号转导途径有关的负性调节因子。目前SOCS家族的成员已达16个之多,该因子能抑制IL-6、IFNγ、IL-2、GH等细胞因子的多种信号转导途径,不仅对JAK-STAT信号途径有负性调控作用,而且还参与其它信号途径的调节,其功能涉及正常组织的分化和器官的发育,因此已为学术界所关注。SOCS-1为该家族中含SH2结构域的SOCS成员之一,本文着重对其分子的结构、负性调节机制及其生物学功能作一综述。     

MicroRNA与肿瘤相关的信号转导通路

信号转导通路在细胞代谢、生长、增殖、应激、发育和凋亡等生命活动中具有极为重要的作用。干扰这些通路将可能影响细胞的正常发育, 甚至导致肿瘤。MicroRNA(miRNA)是近年来在真核生物中发现的、在转录后水平负调节基因表达的一类长度约22个核苷酸的非编码小RNA, 其靶基因数目众多, 生物学功能广泛。在多种肿瘤中发现了miRNA的异常表达, 提示后者与肿瘤发生有关, 可能机制为调控癌基因或肿瘤抑制基因的表达。此外亦发现miRNA的靶基因有许多作用于肿瘤相关的信号转导通路。miRNA在肿瘤发生过程中的重要调控功能预示其将成为人类癌症诊断和治疗方面的新星。     

胰岛素和瘦素抵抗的重要调控因子:细胞因子信号转导抑制因子-3

细胞因子信号转导抑制因子-3(Suppressor of Cytokine Signaling-3,SOCS-3)是细胞信号转导生理抑制剂家族重要成员之一,主要参与负调控生长激素、白介素(IL),肿瘤坏死因子(TNF)等细胞因子信号转导.最近发现,SOCS-3在胰岛素和瘦素抵抗中具有重要调控功能,且与糖尿病关系密切,是未来糖尿病基因治疗的新靶点.该文综述了近年来SOCS-3结构及其对胰岛素和瘦素抵抗的调控机制研究进展,并探讨SOCS-3在糖尿病中的作用.     

SOCS家族在中枢神经系统的研究进展

细胞因子信号抑制因子（SOCS）家族是一类对细胞因子信号通路具有负反馈调节作用的蛋白分子,参与多种细胞因子、生长因子和激素的信号调节。细胞因子对中枢神经系统中的各种生物效应具有广泛多样的调节作用,SOCS家族的许多成员在发育时期和成年的脑内均有表达,SOCS家族不仅与细胞因子信号调节及中枢神经系统多种功能的调节密切相关,而且可能是神经发育和分化的重要调控因子,并参与神经免疫内分泌调节。本文综述了SOCS家族的发现、结构特点、脑内分布以及在中枢神经系统中的功能等方面的研究进展。     

SOCS-1基因与宫颈癌关系的研究新进展

SOCS-1基因定位在染色体16p13.3,编码的SOCS-1蛋白是细胞因子信号转导抑制因子(SOCS)家族的成员之一,最初研究认为SOCS-1主要通过对JAK/STAT信号通路的负性调节从而对多种细胞因子、激素的进行调节,近来有研究表明SOCS-1同样能下调TLR信号通路的活性.细胞因子及TLR信号通路在细胞的生长、成熟、分化及机体的免疫调节中发挥了重要的作用.在多种恶性肿瘤中研究显示SOCS-1呈现基因广泛甲基化及蛋白表达缺失,致JAK/STAT通路的持续活化,与肿瘤的发生发展有关,提示SOCS-1的作用类似于抑癌基因,而在一些肿瘤中则见SOCS-1的高表达,SOCS-1在肿瘤中的作用机制仍存在争议.近年来SOCS-1在宫颈癌中的作用得到重视,但其作用机制尚未明确.而HPV感染可能促进了SOCS-1基因的异常表达,SOCS-1的沉默在宫颈癌的发生发展中可能发挥了重要作用.     

SOCS1基因修饰树突状细胞在肿瘤治疗中的研究进展

树突状细胞是功能最强的抗原提呈细胞,是启动、调节及维持免疫应答的核心环节,以树突状细胞为基础的肿瘤疫苗被认为是最具潜能的肿瘤免疫治疗手段。细胞因子信号通路抑制因子1（suppressor ofcytokine signaling1,SOCS1）是细胞因子信号通路抑制因子（suppressor of cytokine signaling,SOCS）家族的重要成员,广泛参与树突状细胞的发生、成熟和活化,具有负调控树突状细胞功能的重要作用。SOCS1沉默的树突状细胞能够促进自身成熟并增强其诱导的T细胞的抗肿瘤活性。现就国内外关于树突状细胞功能研究及基因修饰的肿瘤疫苗临床试验作一综述,以期对未来的研究有所帮助。     

Suppressor of cytokine signaling 6 in cancer development and therapy: Deciphering its emerging and suppressive roles

The suppressor of cytokine signaling 6 (SOCS6), an emerged important member of SOCS family, has attracted enhancing attention regarding its pivotal role in the development and progression of cancers. As part of negative feedback regulation, SOCS6 has been implicated in attenuating cytokine signal transduction via inhibiting the signaling cascade of activated cytokine receptors and multiple receptor tyrosine kinase signaling. Decreased SOCS6 expression is involved in diverse tumorigenic processes, such as abnormal cell proliferation, evasion of apoptosis, cancer migration, and cancer stem cell maintenance. Herein, this review summarized the mechanisms of SOCS6 regulation underlying multiple pathways. In particular, we focus on the pathological processes of cancer targeted by SOCS6 and discuss its inhibitory role during tumor progression. Also, we focused on the clinical relevance of SOCS6 in cancer biomarker and prognosis, as well as its significance in chemoresistance and radioresistance. In all, this review pave a way to assist in experimental designs and emphasize the potential clinical value of SOCS6 for cancer.     

Restoration of SOCS3 suppresses human lung adenocarcinoma cell growth by downregulating activation of Erk1/2, Akt apart from STAT3

SOCS3 is regarded as a major negative regulator of STAT3. Recent evidence indicates that SOCS3 regulates strength and duration of other signaling pathways including ras/ERK1/2/MAPK, PI3-K/Akt in non-malignant cells. The repression or silence of SOCS3 expression in a few tumor types has led to speculation that loss of SOCS3 gene is closely related to deregulation of multiple signal pathways during tumorigenesis. However, apart from STAT3, little is known in malignant cells about the mechanism by which SOCS3 modulates other intracellular signal cascades such as Erk1/2 and Akt, whose aberrant activation has been implicated in many human tumors. Expression of SOCS3 proved deficient in human lung adenocarcinoma A549 cells, and forced expression of SOCS3 resulted in growth inhibition. Growth suppression due to SOCS3 was associated with attenuated activation of Erk1/2, Akt as well as STAT3. The results suggested that SOCS3, as negative regulators of cytokine signaling, might maintain homeostasis by regulating multiple signaling pathways and reverse cell malignant behavior.     

Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimulated cells

We have shown previously that the Src family kinase Lyn is involved in differentiation signals emanating from activated erythropoietin (Epo) receptors. The importance of Lyn to red cell maturation has been highlighted by Lyn-/- mice developing anemia. Here we show that Lyn interacts with C-terminal Src kinase-binding protein (Cbp), an adaptor protein that recruits negative regulators C-terminal Src kinase (Csk)/Csk-like protein-tyrosine kinase (Ctk). Lyn phosphorylated Cbp on several tyrosine residues, including Tyr314, which recruited Csk/Ctk to suppress Lyn kinase activity. Intriguingly, phosphorylated Tyr314 also bound suppressor of cytokine signaling 1 (SOCS1), another well characterized negative regulator of cell signaling, resulting in elevated ubiquitination, and degradation of Lyn. In Epo-responsive primary cells and cell lines, Lyn rapidly phosphorylated Cbp, suppressing Lyn kinase activity via Csk/Ctk within minutes of Epo stimulation; hours later, SOCS1 bound to Cbp and was involved in the ubiquitination and turnover of Lyn protein. Thus, a single phosphotyrosine residue on Cbp coordinates a two-phase process involving distinct negative regulatory pathways to inactivate, then degrade, Lyn.     

Cloning and expression of CIS6, chromosome assignment to 3p22 and 2p21 by in situ hybridization

A family of negative regulators of JAK signaling pathway referred to as suppressor of cytokines signaling (SOCS) or cytokine-inducible SH2 protein (CIS) has been recently identified. In order to find additional members of this family, we have used a consensus amino acid sequence contained in the well-conserved central SH2 domain to search DNA databases. We isolated cDNA coding for the human homologue of SOCS-5, referred to as CIS6. Northern blot analysis revealed CIS6 mRNA expression in various tissues such as heart, muscle, spleen, and thymus and in all myeloma cell lines examined. The gene was assigned to human chromosome bands 2p21 and 3p22 by in situ hybridization. CIS6 is structurally related to other members of the CIS family and therefore could act as a negative regulator of signal transduction.     

SOCS regulation of the JAK/STAT signalling pathway

The suppressor of cytokine signalling (SOCS) proteins were, as their name suggests, first described as inhibitors of cytokine signalling. While their actions clearly now extend to other intracellular pathways, they remain key negative regulators of cytokine and growth factor signalling. In this review we focus on the mechanics of SOCS action and the complexities of the mouse models that have underpinned our current understanding of SOCS biology.     

Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling

Suppressors of cytokine signaling (SOCS) are Src homology-2-containing proteins originally identified as negative regulators of cytokine signaling. Accumulating evidence indicates a role for SOCS proteins in the regulation of additional signaling pathways including receptor tyrosine kinases. Notably, SOCS36E, the Drosophila ortholog of mammalian SOCS5, was recently implicated as a negative regulator of the Drosophila ortholog of EGFR. In this study, we aimed at characterizing the role of SOCS5 in the negative regulation of EGFR. Here we show that the expression of SOCS5 and its closest homolog SOCS4 is elevated in cells following treatment with EGF, similar to several negative feedback regulators of EGFR whose expression is up-regulated upon receptor activation. The expression of SOCS5 led to a marked reduction in EGFR expression levels by promoting EGFR degradation. The reduction in EGFR levels and EGF-induced signaling in SOCS5-expressing cells requires both the Src homology-2 and SOCS box domains of SOCS5. Interestingly, EGFR is degraded by SOCS5 prior to EGF treatment in a ligand- and c-Cbl-independent manner. SOCS5 can associate with EGFR and can also bind the ElonginBC protein complex via its SOCS box, which may recruit an E3 ubiquitin ligase to promote EGFR degradation. Thus, we have characterized a novel function for SOCS5 in regulating EGFR and discuss its potential role in controlling EGFR homeostasis.     

Feedback inhibitors of the epidermal growth factor receptor signaling pathways

The epidermal growth factor receptor family tyrosine kinases transduce signals for cell proliferation and migration and contribute to tumorigenesis. A recent extensive research has highlighted the major roles of the negative regulators of complex epidermal growth factor receptor signaling networks. These regulators fine-tune signaling under physiological conditions. When their expression is downregulated, the resultant aberrant epidermal growth factor receptor signaling may promote cell proliferation and migration, leading to increased tumorigenesis. In this paper, I review specific feedback inhibitors that target epidermal growth factor receptors preferentially, via multiple modes of action. The inhibitors include mitogen-inducible gene-6 (Mig-6)/receptor-associated late transducer (RALT)/Gene 33, fibroblast growth factor receptor substrate 2beta (FRS2beta)/suc1-associated neurotrophic factor target-2 (SNT-2)/FRS3, suppressor of cytokine signaling 3 (SOCS3)/SOCS4/SOCS5, and leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1). Although only fragmentary evidence is available regarding these inhibitors, they might be useful as cancer biomarkers, and the development of drugs that target them would certainly advance personalized medicine in the near future.